Avmapki Fakzynja Co Pack
Named-patient access overview. Avmapki Fakzynja Co Pack is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Avmapki Fakzynja Co Pack
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Avmapki Fakzynja Co Pack
Avmapki Fakzynja Co-Pack (avutometinib plus defactinib) is manufactured by Verastem Oncology and was approved by the US FDA in 2025 for adult patients with KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC). Both halves of the co-pack are oral small molecules taken on a structured cycle.
The regimen targets the RAS/MAPK pathway from two angles. Avutometinib is a RAF/MEK clamp that binds the RAF-MEK complex and blocks the feedback reactivation of MEK seen with single-agent MEK inhibition. Defactinib is a focal adhesion kinase (FAK) inhibitor that suppresses an adaptive resistance node. The two molecules are co-packaged so the dosing schedule for each half is paired correctly at the patient level.
Avmapki Fakzynja Co-Pack may be accessible to international patients through Named Patient Program or personal-import pathways where the co-pack is not yet locally registered.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Avmapki Fakzynja Co Pack
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Avmapki Fakzynja Co Pack for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Avmapki Fakzynja Co Pack is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list avutometinib and defactinib as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Access by country
Reserve Meds publishes a detailed country deep-dive for Avmapki Fakzynja Co Pack in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Avmapki Fakzynja Co Pack
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Avmapki Fakzynja Co Pack if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Avmapki Fakzynja Co Pack for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Avmapki Fakzynja Co Pack through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Avmapki Fakzynja Co Pack. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Avmapki Fakzynja Co Pack through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Avmapki Fakzynja Co Pack to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Avmapki Fakzynja Co Pack to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Avmapki Fakzynja Co Pack cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Avmapki Fakzynja Co Pack?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.